Open AccessRituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis
Author(s) -
Koratala Abhilash,
Zeng Xu
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1371
Subject(s) - membranoproliferative glomerulonephritis , medicine , rituximab , cryoglobulinemia , cryoglobulins , hepatitis c virus , immunology , hepatitis c , vasculitis , monoclonal , glomerulonephritis , virology , monoclonal antibody , antibody , disease , virus , kidney
Key Clinical Message Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV‐related vasculitis and may evade the need for dialysis as in our patient.